Trastuzumab emtansine
- Generic Name
- Trastuzumab emtansine
- Brand Names
- Kadcyla
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1018448-65-1
- Unique Ingredient Identifier
- SE2KH7T06F
- Background
Trastuzumab emtansine, formerly called Trastuzumab-DM1 (T-DM1) is a first-in-class HER2 antibody drug conjugate (ADC) comprised of Genentech's trastuzumab antibody linked to ImmunoGen's cell-killing agent, DM1. T-DM1 combines two strategies-- anti-HER2 activity and targeted intracellular delivery of the potent anti-microtubule agent, DM1 (a maytansine deriva...
- Indication
Used in HER2-positive, metastatic breast cancer patients who have already used taxane and/or trastuzumab for metastatic disease or had their cancer recur within 6 months of adjuvant treatment.
- Associated Conditions
- HER2-Positive Early Stage Breast Cancer, HER2-positive, Metastatic Breast Cancer
- Associated Therapies
- -
Deciphering Antitumour Response and Resistance With INtratumour Heterogeneity
- Conditions
- Interventions
- First Posted Date
- 2014-12-11
- Last Posted Date
- 2023-12-04
- Lead Sponsor
- University College, London
- Target Recruit Count
- 50
- Registration Number
- NCT02314481
- Locations
- 🇬🇧
Univeristy College London Hospital, London, United Kingdom
A Study of Trastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor (HER)2 Immunohistochemistry (IHC)-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
- First Posted Date
- 2014-11-13
- Last Posted Date
- 2019-08-07
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 49
- Registration Number
- NCT02289833
- Locations
- 🇵🇱
Medical University of Gdansk, Gdansk, Poland
🇵🇱Mazowieckie Centrum Leczenia Chorob Pluc I Gruzlicy; Oddzial Iii, Otwock, Poland
🇨🇭CHUV; Departement d'Oncologie, Lausanne, Switzerland
A Dose-Escalation Study Evaluating the Combination of Trastuzumab Emtansine (T-DM1) With Neratinib in Women With Metastatic HER2-Positive Breast Cancer
- First Posted Date
- 2014-09-10
- Last Posted Date
- 2023-01-26
- Lead Sponsor
- NSABP Foundation Inc
- Target Recruit Count
- 49
- Registration Number
- NCT02236000
- Locations
- 🇺🇸
University of Pittsburgh, Pittsburgh, Pennsylvania, United States
🇺🇸Cancer Care Specialists of Central Illinois, Decatur, Illinois, United States
🇺🇸UPMC- St. Margaret, Pittsburgh, Pennsylvania, United States
A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine Versus the Combination of Trastuzumab Plus Docetaxel in Patients With HER2-positive Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2014-05-21
- Last Posted Date
- 2017-03-07
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 49
- Registration Number
- NCT02144012
A Study Evaluating Trastuzumab Emtansine Plus Pertuzumab Compared With Chemotherapy Plus Trastuzumab and Pertuzumab for Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2014-05-06
- Last Posted Date
- 2019-07-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 444
- Registration Number
- NCT02131064
- Locations
- 🇺🇸
Cancer Care Assoc Med Group, Los Angeles, California, United States
🇺🇸New England Cancer Specialists, Scarborough, Maine, United States
🇺🇸Hope A Women's Cancer Center, Asheville, North Carolina, United States
Neoadjuvant TDM1 With Lapatinib and Abraxane Compared With Trastuzumab Plus Pertuzumab With Paclitaxel
- Conditions
- Interventions
- First Posted Date
- 2014-02-27
- Last Posted Date
- 2021-09-22
- Lead Sponsor
- The Methodist Hospital Research Institute
- Target Recruit Count
- 32
- Registration Number
- NCT02073487
- Locations
- 🇺🇸
Houston Methodist Hospital, Houston, Texas, United States
🇺🇸Houston Methodist Hospital Sugar Land, Sugar Land, Texas, United States
🇺🇸Houston Methodist Hospital Willowbrook, Houston, Texas, United States
T-DM1 With Abraxane and Lapatinib for Metastatic HER2 Positive Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2014-02-27
- Last Posted Date
- 2019-04-16
- Lead Sponsor
- Jenny C. Chang, MD
- Target Recruit Count
- 24
- Registration Number
- NCT02073916
- Locations
- 🇺🇸
Houston Methodist Hospital, Houston, Texas, United States
A Study of Tucatinib (ONT-380) Combined With Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2+ Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2013-11-14
- Last Posted Date
- 2020-09-21
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 57
- Registration Number
- NCT01983501
- Locations
- 🇨🇦
Princess Margaret Cancer Centre, Toronto, Ontario, Canada
🇨🇦Hospital de la Cite-de-la-Sante, Laval, Quebec, Canada
🇺🇸Sarah Cannon Research Institute, Nashville, Tennessee, United States
A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer
- First Posted Date
- 2013-10-21
- Last Posted Date
- 2022-06-14
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1846
- Registration Number
- NCT01966471
- Locations
- 🇨🇦
Princess Margaret Cancer Center, Toronto, Ontario, Canada
🇦🇺Chris O'Brien Lifehouse, Camperdown, New South Wales, Australia
🇯🇵Niigata Cancer Ctr Hospital; Breast Surgery, Niigata, Japan
T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)
- Conditions
- Interventions
- First Posted Date
- 2013-05-15
- Last Posted Date
- 2024-07-11
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 512
- Registration Number
- NCT01853748
- Locations
- 🇺🇸
Rex Cancer Center, Raleigh, North Carolina, United States
🇺🇸Johns Hopkins - Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
🇺🇸Memorial Sloan Kettering Cancer Center Westchester, Harrison, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.